# Table of Contents

1.0 INTRODUCTION ...........................................1  
   1.1 Purpose ..............................................2  
   1.2 Scope .............................................3  

2.0 ABBREVIATIONS ........................................4  

3.0 EXISTING GUIDANCE DOCUMENTS FOR VACCINES...4  

4.0 CONTROL STRATEGY FROM PROCESS DEVELOPMENT TO VACCINE LIFECYCLE MANAGEMENT ........................................6  
   4.1 Key Elements and Considerations for Establishing Vaccines Control Strategy ........................................6  
   4.2 Considerations for Setting and Managing Vaccine Specifications ........................................7  
      4.2.1 Considerations for Setting Vaccine Specifications: Critical Quality Attributes and Ranges .................7  
      4.2.2 Approaches for Analytical Procedures Selection in Specifications ........................................9  
      4.2.3 Managing Vaccine Specifications throughout Product Lifecycle ........................................10  
   4.3 Establishing Process Parameter Classifications and Lifecycle Management ........................................10  
      4.3.1 Considerations for Establishing Process Parameter Classifications ........................................10  
      4.3.2 Considerations for Reclassification of Parameters ..............................................11  

5.0 COMPARABILITY ASSESSMENTS: ENabler FOR CHANGES DURING DEVELOPMENT AND AFTER APPROVAL ........................................12  
   5.1 Benefits of Comparability Protocols and Comparability Exercises for Vaccines ........................................12  
   5.2 Challenges of Using Comparability Assessments for Vaccines ........................................13  
   5.3 Recommended Considerations for Comparability Protocols and Comparability Assessments for Vaccines ........................................14  
   5.4 Suggested Best Practices for Comparability Assessments ..............................................16  

6.0 CONSIDERATIONS FOR VACCINES LIFECYCLE MANAGEMENT ........................................19  
   6.1 Nonregulatory Considerations for Management of Post-Approval Changes ........................................20  
      6.1.1 Technical Considerations for Management of Changes ........................................20  
      6.1.2 Validation Considerations for Management of Changes ........................................26  
      6.1.3 Relying on Effective Pharmaceutical Quality System for Management of Changes ........................................29  
      6.1.4 Use of a Risk-Based Approach and Development of an Effective PQS ........................................29  
   6.2 Regulatory Considerations for Management of Post-Approval Changes ........................................30  
      6.2.1 General Regulatory Considerations for Management of PACs ........................................31  
      6.2.2 Key Considerations for Post-Approval Change Submissions ........................................32  
      6.2.3 Using the Regulatory Mechanism of ICH Q12 ..............................................33  
      6.2.4 Strategies for Multinational and Multiproduct Submissions ........................................36  

7.0 CONCLUSION ..............................................37  

8.0 REFERENCES ..............................................38  

## FIGURES AND TABLES INDEX

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1.0-1</td>
<td>Complexity of Vaccine Development and Lifecycle Management</td>
<td>1</td>
</tr>
<tr>
<td>Table 1.0-1</td>
<td>Diversity in Vaccine Platforms</td>
<td>2</td>
</tr>
<tr>
<td>Table 3.0-1</td>
<td>Summary of Selected Guidance and Industry Documents and Relevance to Strategies for Vaccines Development and Lifecycle Management</td>
<td>5</td>
</tr>
<tr>
<td>Figure 4.1-1</td>
<td>Holistic Control Strategy for Vaccines Development and Lifecycle</td>
<td>6</td>
</tr>
<tr>
<td>Table 4.2.1-1</td>
<td>Examples of Quality Attributes with Additional Considerations for Vaccines</td>
<td>8</td>
</tr>
<tr>
<td>Table 4.3.2-1</td>
<td>Examples of Parameter Classification Changes</td>
<td>11</td>
</tr>
<tr>
<td>Table 5.2-1</td>
<td>Examples where Vaccine Changes Could be Justified with Analytical or Target Clinical Data</td>
<td>14</td>
</tr>
<tr>
<td>Table 5.3-1</td>
<td>Examples of Quality Attributes that Could Leverage Analytical Comparability</td>
<td>15</td>
</tr>
<tr>
<td>Table 5.3-2</td>
<td>Examples where Comparability could be Considered without Need for Additional Clinical Studies</td>
<td>15</td>
</tr>
<tr>
<td>Table 5.3-3</td>
<td>Examples when Clinical Data may be Required to Support Comparability</td>
<td>16</td>
</tr>
<tr>
<td>Table 5.4-1</td>
<td>Practical Considerations for Comparability Assessments</td>
<td>16</td>
</tr>
<tr>
<td>Figure 5.4-2</td>
<td>Timing of Implementation Using</td>
<td></td>
</tr>
</tbody>
</table>

---
Table 5.4-2  Common Comparability Protocols Received by U.S. FDA, 2004-2014 ................. 18
Figure 6.0-1  Representation of the Complexity in Managing Multinational Regulatory Submissions............................... 19
Figure 6.0-2  Vaccine Inventory Complexity Management ................................................. 20
Figure 6.1-1  Vaccine Lifecycle Management Complexity ..................................................... 21
Table 6.1.1.2-1  Examples of Working Cell Bank Manufacturing Changes, Potential Classification, and Supporting Data Expectations........................................... 23
Table 6.1.2.3-1  Matrix Approach using Three Strategies ...................................................... 27
Figure 6.1.2.3-1  Representation of Matrix Validation Approach ............................................. 28
Table 6.1.2.3-2  Illustration of a Matrix Approach for Filling Process PPQ ................................. 28
Figure 6.1.4-1  Risk-Based Assessment of PACs and Determination of Regulatory Reporting Category ...................................................... 30
Table 6.2.1-1  Overview of the Current Situation and Proposals for Improvement......................... 32
Figure 7.0-1  Key Elements to Consider during Development of a Vaccine Strategy ............. 38